Articles
28 May 2009
Vol. 1 No. 2: Is Elimination of Minimal Residual Disease Significant for the Outcome of CLL? The Role of Alemtuzumab
https://doi.org/10.4081/hmr.v1i2.223

Re-evaluation of response criteria in chronic lymphocytic leukemia and the significance of minimal residual disease

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
232
Views
791
Downloads

Authors

Michael Hallek
support@pagepress.org
Chronic lymphocytic leukemia (CLL) is one of the most common lymphoid malignancies in the developed world, affecting approximately 120,000 people annually in the USA and Europe. The disease has a very variable clinical course; many patients survive for decades without requiring treatment and die of unrelated causes, whereas other patients develop more aggressive forms of the disease that lead to an early death. Traditionally, the approach to the management of CLL has been watchful waiting, with clinical staging (Rai or Binet) providing limited prognostic information

Altmetrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



Re-evaluation of response criteria in chronic lymphocytic leukemia and the significance of minimal residual disease. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 1(2), 1-4. https://doi.org/10.4081/hmr.v1i2.223